295 related articles for article (PubMed ID: 20927318)
1. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
2. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
3. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.
Hotz HG; Gill PS; Masood R; Hotz B; Buhr HJ; Foitzik T; Hines OJ; Reber HA
J Gastrointest Surg; 2002; 6(2):159-66; discussion 166. PubMed ID: 11992800
[TBL] [Abstract][Full Text] [Related]
4. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
[TBL] [Abstract][Full Text] [Related]
5. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2.
Backer MV; Budker VG; Backer JM
J Control Release; 2001 Jul; 74(1-3):349-55. PubMed ID: 11489517
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
Fukasawa M; Korc M
Clin Cancer Res; 2004 May; 10(10):3327-32. PubMed ID: 15161686
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
8. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins.
Backer MV; Backer JM
Bioconjug Chem; 2001; 12(6):1066-73. PubMed ID: 11716701
[TBL] [Abstract][Full Text] [Related]
9. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.
Seeliger H; Camaj P; Ischenko I; Kleespies A; De Toni EN; Thieme SE; Blum H; Assmann G; Jauch KW; Bruns CJ
Mol Cancer Res; 2009 Feb; 7(2):189-98. PubMed ID: 19208748
[TBL] [Abstract][Full Text] [Related]
10. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling.
Qin J; Chen X; Yu-Lee LY; Tsai MJ; Tsai SY
Cancer Res; 2010 Nov; 70(21):8812-21. PubMed ID: 20978203
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
13. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
16. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
17. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
18. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
[TBL] [Abstract][Full Text] [Related]
19. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
[TBL] [Abstract][Full Text] [Related]
20. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]